Recent Press Releases

Bristol-Myers Squibb Signs Exclusive Agreement with Bavarian Nordic for PROSTVAC®, a Prostate-Specific Antigen-Targeting Cancer Immunotherapy

Bristol-Myers Squibb Signs Exclusive Agreement with Bavarian Nordic for PROSTVAC®, a Prostate-Specific Antigen-Targeting Cancer Immunotherapy Bavarian Nordic to receive up to $975 million,...

Pfizer Receives European Approval for New Indication for Prevenar 13 for Prevention of Vaccine-Type Pneumococcal Pneumonia in Adults

Label Also Updated to Include Data From the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) Tuesday, March 3, 2015 - 8:35am EST Pfizer Inc. (NYSE:PFE) announced...

Targovax appoints Øystein Soug as new CFO

OSLO, Norway--(BUSINESS WIRE)--Targovax is pleased to announce Mr. Øystein Soug as the new CFO of the Company from June 1, 2015 Mr. Øystein Soug, has been the CFO of the late-stage...

Themis Bioscience's Chikungunya Vaccine Study Results Published in The Lancet Infectious Diseases

Phase 1 trial of the vaccine candidate which was developed under an R&D collaboration between Themis Bioscience GmbH and the Institut Pasteur (Paris) shows good immunogenicity, safety and...

Merck's 9-Valent HPV Vaccine, GARDASIL®9, Recommended by CDC's Advisory Committee on Immunization Practices for Females Aged 9-26 and Males Aged 9-21

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Centers for Disease Control and Prevention's (CDC's)...

First patient included in US Diamyd® and GABA diabetes study

Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) informs that the first patient has been randomized and dosed in a pioneering study combining the diabetes vaccine Diamyd® with GABA...

Aduro Biotech Collaborates with Leaders in Cancer Research on Investigator-Sponsored Phase 2 Trial Combining Aduro's Innovative Immunotherapies with Anti-PD-1 Technology to Treat Patients with Advanced Pancreatic Cancer

- Combination Immunotherapeutic Regimen Designed to Enhance Cancer Fighting Competency of Immune Cells - February 26, 2015 08:00 AM Eastern Standard Time BERKELEY, Calif.--(BUSINESS WIRE)--Aduro...

PROVENGE® (sipuleucel-T) Demonstrates Sustained Immune Response Two Years after Treatment in Biochemically-Recurrent Prostate Cancer

PROVENGE® (sipuleucel-T) Demonstrates Sustained Immune Response Two Years after Treatment in Biochemically-Recurrent Prostate Cancer 02/25/2015 - New, long-term preliminary data from Phase II...

NewLink Genetics Corporation Announces Clinical Development Milestone Achieved With Merck for Ebola Vaccine Candidate

$20 Million Milestone Payment AMES, Iowa, Feb. 19, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) today announced that it had received notification from Merck (NYSE:MRK) that...

Pre-Booking for Flublok® Influenza Vaccine Now Available from Cardinal Health and McKesson

MERIDEN, Conn., Feb. 24, 2015 /PRNewswire/ -- Protein Sciences Corporation announced today it has expanded distribution options for its revolutionary Flublok influenza vaccine and that pre-booking...

Bavarian Nordic Announces Updated Overall Survival Data from Combination Immunotherapy Data of PROSTVAC plus Ipilimumab at the 2015 Genitourinary Cancers Symposium

Approximately 20% of men with advanced prostate cancer treated with PROSTVAC and Ipilimumab remain alive at 80 months after initiating treatment KVISTGAARD, Denmark, February 24, 2015 - Bavarian...

Pfizer Announces Positive Top-line Results Of A Phase 2 Study Of TRUMENBA® (Meningococcal Group B Vaccine) Co-Administered With Routine Meningococcal (A, C, Y, and W) And Tetanus, Diptheria And Pertussis (Tdap) Vaccines In Adolescents

Data from Recently Completed Phase 3 Study Also Demonstrated Safety and Tolerability of TRUMENBA® in Adolescents and Young Adults NEW YORK, Feb 24, 2015 (BUSINESS WIRE) -- Pfizer Inc. PFE,...

Advaxis Completes $23 Million Financing

INSTITUTIONAL OWNERSHIP IN ADVAXIS CONTINUES TO INCREASE PRINCETON, N.J., Feb. 18, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer...

Agilvax Announces Strategic Collaboration with Humabs BioMed SA to Develop Targeted Vaccines and Immunotherapies

ALBUQUERQUE, N.M., Feb. 17, 2015 /PRNewswire/ -- Agilvax, Inc. today announced a collaboration with Switzerland based Humabs BioMed that will contribute to the rapid advancement of Agilvax's...

IDRI Announces $4M BARDA Cooperative Agreement To Establish Adjuvant Hub

SEATTLE, Feb. 19, 2015 /PRNewswire-USNewswire/ -- The international outbreak of Ebola in 2014 serves as a reminder for the need to be proactive in preparing for the rapid spread of any newly...

VaxInnate Receives Extension of Contract from BARDA for Development of Seasonal and Pandemic Influenza Vaccines

Allows for Non-Dilutive Funding of $53 Million Cranbury, NJ, Feb. 17, 2015 -- VaxInnate Corporation, a biotechnology firm pioneering a breakthrough vaccine technology, today announced that it has...

IAVI Receives GSK Funding for the Human Vaccines Project to Accelerate Development of Vaccines for Infectious Diseases and Cancer

NEW YORK, Feb. 17, 2015 /PRNewswire-USNewswire/ -- The International AIDS Vaccine Initiative (IAVI) has received a grant of US$350,000 from GSK to support implementation of the Human Vaccines...

NOVAVAX ANNOUNCES INITIATION OF EBOLA VACCINE PHASE 1 CLINICAL TRIAL SUPPORTED BY NON-HUMAN PRIMATE CHALLENGE DATA AND DOCUMENTED RAPID MANUFACTURING CAPABILITIES

Initiation of Enrollment of Phase 1 Clinical Trial of Ebola GP Vaccine Non-Human Primate Challenge Data Signal Breakthrough in Ebola Vaccine Development Rapid Manufacturing Process of Ebola...

VaxInnate Receives Extension of Contract from BARDA for Development of Seasonal and Pandemic Influenza Vaccines

VaxInnate Receives Extension of Contract from BARDA for Development of Seasonal and Pandemic Influenza Vaccines Allows for Non-Dilutive Funding of $53 Million Cranbury, NJ, Feb. 17, 2015 -- VaxInnate...

Valeant Pharmaceuticals Announces Expiration Of Bid Deadline In Connection With Agreement To Acquire Assets From Dendreon

02/10/2015 LAVAL, Quebec, Feb. 10, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that they have been advised by Dendreon Corporation that...